Review



dok2 mouse monoclonal antibody  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Santa Cruz Biotechnology dok2 mouse monoclonal antibody
    Serum <t>anti-DOK2</t> antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.
    Dok2 Mouse Monoclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dok+2/Dok-2+Antibody/pmc12456515-154-5-11
    Average 93 stars, based on 23 article reviews
    dok2 mouse monoclonal antibody - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Identification of anti-DOK2 antibodies in patients with autoimmune hepatitis via a human protein microarray"

    Article Title: Identification of anti-DOK2 antibodies in patients with autoimmune hepatitis via a human protein microarray

    Journal: Hepatology Communications

    doi: 10.1097/HC9.0000000000000807

    Serum anti-DOK2 antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.
    Figure Legend Snippet: Serum anti-DOK2 antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.

    Techniques Used: Comparison

    Related Articles

    Incubation:

    Article Title: Alteration of platelet GPVI signaling in ST-elevation myocardial infarction patients demonstrated by a combination of proteomic, biochemical, and functional approaches
    Article Snippet: Following the electrophoresis, proteins were transferred onto polyvinylidene difluoride (PVDF) membranes (GE Healthcare). .. The membranes were blocked in 5% BSA in TBS-T (20 mM Tris-HCl (pH 7.6), 150 mM NaCl and 0.1% Tween 20) overnight at 4 °C and incubated for 90 min at room temperature with the following primary antibodies: mouse-anti PLCɣ2 (sc-5283), rabbit-anti SLP-76 (sc-9062), rabbit-anti Dok-2 (sc-13952), all of them from Santa Cruz Biotechnology, Inc. (Delaware, CA, USA); rabbit-anti 4G10 mouse antiphosphotirosine mAb (MAB1501) from Millipore; rabbit anti-GAPDH (G9545) from Sigma Aldrich; and G6f (1:1000), produced by CovalAB UK (Cambridge, UK), as previously indicated . ..

    Article Title: Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling
    Article Snippet: .. For immunoblotting, immunoprecipitates or cleared cell lysates were separated by SDS-PAGE and transferred to PVDF membrane (Bio-Rad Laboratories), which was then incubated with antibodies to phospho-ERK (Thr202/Tyr204), phospho-p38 (Thr180/Tyr182), phospho–IκB-α (Cell Signaling), phospho-JNK (Thr183/Tyr185), ERK, IκB-α, Dok-2 (H192), p120 rasGAP (Santa Cruz Biotechnology, Inc.), or phosphotyrosine (4G10; Upstate Biotechnology), followed by incubation with secondary horse radish peroxidase–labeled (Amersham Biosciences) or AP-labeled (Santa Cruz Biotechnology, Inc.) antibodies. .. The blots were visualized with the ECL system (Amersham Biosciences) or BCIP/NBT system (Promega).

    Article Title: Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling
    Article Snippet: .. For immunoprecipitation, cell lysates were cleared and incubated with antibodies to mouse Dok-1 (A3) or Dok-2 (M20; Santa Cruz Biotechnology, Inc.) followed by incubation with protein G–Sepharose (Amersham Biosciences). ..

    Article Title: Dok-1 and Dok-2 are negative regulators of T cell receptor signaling.
    Article Snippet: CD4+ splenic T cells (2 3 107 per 0.2 ml) purified by magnetic field exclusion or 25-14 T cells (1 3 107 per 0.2 ml) were treated with biotinylated anti-CD3e mAbs (10 lg ml 1) followed by cross-linking with streptavidin (25 lg ml 1) at 37 C. These cells were solubilized with the lysis buffer (1% NP-40, 150 mM NaCl, 10 mM Tris at pH 7.4, 0.5 mM EDTA, 10 mM NaF, 1 mM sodium orthovanadate, 10 lM sodium molybdate, 2 lg ml 1 aprotinin, 1 mM benzamidine, 5 lg ml 1 chymostatin, 5 lg ml 1 leupeptin, 1 lg ml 1 pepstatin A and 0.2 mM phenylmethylsulphonylfluoride), and cleared lysates (whole cell lysates) were subjected to immunoblotting with antibodies to phospho-ZAP-70, phospho-LAT, phospho-Erk (Cell Signaling, Danvers, MA, USA), Erk2 (Santa Cruz, Santa Cruz, CA, USA) or FLAG-tag (Sigma). .. Otherwise, they were sequentially incubated with antibodies to TCRf (Santa Cruz), Dok-1 or Dok-2 (Santa Cruz) and protein G-Sepharose (Amersham Biosciences, Buckinghamshire, UK), and immunoprecipitates were subjected to immunoblotting with antibodies to TCRf, phosphotyrosine (4G10, Millipore, Billerica, MA, USA), Dok-1, Dok-2 or FLAG-tag. ..

    Produced:

    Article Title: Alteration of platelet GPVI signaling in ST-elevation myocardial infarction patients demonstrated by a combination of proteomic, biochemical, and functional approaches
    Article Snippet: Following the electrophoresis, proteins were transferred onto polyvinylidene difluoride (PVDF) membranes (GE Healthcare). .. The membranes were blocked in 5% BSA in TBS-T (20 mM Tris-HCl (pH 7.6), 150 mM NaCl and 0.1% Tween 20) overnight at 4 °C and incubated for 90 min at room temperature with the following primary antibodies: mouse-anti PLCɣ2 (sc-5283), rabbit-anti SLP-76 (sc-9062), rabbit-anti Dok-2 (sc-13952), all of them from Santa Cruz Biotechnology, Inc. (Delaware, CA, USA); rabbit-anti 4G10 mouse antiphosphotirosine mAb (MAB1501) from Millipore; rabbit anti-GAPDH (G9545) from Sigma Aldrich; and G6f (1:1000), produced by CovalAB UK (Cambridge, UK), as previously indicated . ..

    Western Blot:

    Article Title: Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling
    Article Snippet: .. For immunoblotting, immunoprecipitates or cleared cell lysates were separated by SDS-PAGE and transferred to PVDF membrane (Bio-Rad Laboratories), which was then incubated with antibodies to phospho-ERK (Thr202/Tyr204), phospho-p38 (Thr180/Tyr182), phospho–IκB-α (Cell Signaling), phospho-JNK (Thr183/Tyr185), ERK, IκB-α, Dok-2 (H192), p120 rasGAP (Santa Cruz Biotechnology, Inc.), or phosphotyrosine (4G10; Upstate Biotechnology), followed by incubation with secondary horse radish peroxidase–labeled (Amersham Biosciences) or AP-labeled (Santa Cruz Biotechnology, Inc.) antibodies. .. The blots were visualized with the ECL system (Amersham Biosciences) or BCIP/NBT system (Promega).

    Article Title: CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth
    Article Snippet: .. Expression of specific proteins was revealed by immunoblotting with antibodies directed against Dok-1, Dok-2, Shc, Csk, SHP-1, SHP-2, or SHIP-1 Ab, which were generated in the Veillette laboratory , ; Ras-GAP (B4F8; Santa Cruz Biotechnologies, Dallas, TX); or β-actin (C4, Santa Cruz Technologies). ..

    Article Title: CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth.
    Article Snippet: .. Expression of specific proteins was revealed by immunoblotting with antibodies directed against Dok-1, Dok-2, Shc, Csk, SHP-1, SHP-2, or SHIP-1 Ab, which were generated in the Veillette laboratory38,54; RasGAP (B4F8; Santa Cruz Biotechnologies, Dallas, TX); or β-actin (C4, Santa Cruz Technologies). ..

    Article Title: Dok-1 and Dok-2 are negative regulators of T cell receptor signaling.
    Article Snippet: CD4+ splenic T cells (2 3 107 per 0.2 ml) purified by magnetic field exclusion or 25-14 T cells (1 3 107 per 0.2 ml) were treated with biotinylated anti-CD3e mAbs (10 lg ml 1) followed by cross-linking with streptavidin (25 lg ml 1) at 37 C. These cells were solubilized with the lysis buffer (1% NP-40, 150 mM NaCl, 10 mM Tris at pH 7.4, 0.5 mM EDTA, 10 mM NaF, 1 mM sodium orthovanadate, 10 lM sodium molybdate, 2 lg ml 1 aprotinin, 1 mM benzamidine, 5 lg ml 1 chymostatin, 5 lg ml 1 leupeptin, 1 lg ml 1 pepstatin A and 0.2 mM phenylmethylsulphonylfluoride), and cleared lysates (whole cell lysates) were subjected to immunoblotting with antibodies to phospho-ZAP-70, phospho-LAT, phospho-Erk (Cell Signaling, Danvers, MA, USA), Erk2 (Santa Cruz, Santa Cruz, CA, USA) or FLAG-tag (Sigma). .. Otherwise, they were sequentially incubated with antibodies to TCRf (Santa Cruz), Dok-1 or Dok-2 (Santa Cruz) and protein G-Sepharose (Amersham Biosciences, Buckinghamshire, UK), and immunoprecipitates were subjected to immunoblotting with antibodies to TCRf, phosphotyrosine (4G10, Millipore, Billerica, MA, USA), Dok-1, Dok-2 or FLAG-tag. ..

    SDS Page:

    Article Title: Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling
    Article Snippet: .. For immunoblotting, immunoprecipitates or cleared cell lysates were separated by SDS-PAGE and transferred to PVDF membrane (Bio-Rad Laboratories), which was then incubated with antibodies to phospho-ERK (Thr202/Tyr204), phospho-p38 (Thr180/Tyr182), phospho–IκB-α (Cell Signaling), phospho-JNK (Thr183/Tyr185), ERK, IκB-α, Dok-2 (H192), p120 rasGAP (Santa Cruz Biotechnology, Inc.), or phosphotyrosine (4G10; Upstate Biotechnology), followed by incubation with secondary horse radish peroxidase–labeled (Amersham Biosciences) or AP-labeled (Santa Cruz Biotechnology, Inc.) antibodies. .. The blots were visualized with the ECL system (Amersham Biosciences) or BCIP/NBT system (Promega).

    Membrane:

    Article Title: Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling
    Article Snippet: .. For immunoblotting, immunoprecipitates or cleared cell lysates were separated by SDS-PAGE and transferred to PVDF membrane (Bio-Rad Laboratories), which was then incubated with antibodies to phospho-ERK (Thr202/Tyr204), phospho-p38 (Thr180/Tyr182), phospho–IκB-α (Cell Signaling), phospho-JNK (Thr183/Tyr185), ERK, IκB-α, Dok-2 (H192), p120 rasGAP (Santa Cruz Biotechnology, Inc.), or phosphotyrosine (4G10; Upstate Biotechnology), followed by incubation with secondary horse radish peroxidase–labeled (Amersham Biosciences) or AP-labeled (Santa Cruz Biotechnology, Inc.) antibodies. .. The blots were visualized with the ECL system (Amersham Biosciences) or BCIP/NBT system (Promega).

    Expressing:

    Article Title: CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth
    Article Snippet: .. Expression of specific proteins was revealed by immunoblotting with antibodies directed against Dok-1, Dok-2, Shc, Csk, SHP-1, SHP-2, or SHIP-1 Ab, which were generated in the Veillette laboratory , ; Ras-GAP (B4F8; Santa Cruz Biotechnologies, Dallas, TX); or β-actin (C4, Santa Cruz Technologies). ..

    Article Title: CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth.
    Article Snippet: .. Expression of specific proteins was revealed by immunoblotting with antibodies directed against Dok-1, Dok-2, Shc, Csk, SHP-1, SHP-2, or SHIP-1 Ab, which were generated in the Veillette laboratory38,54; RasGAP (B4F8; Santa Cruz Biotechnologies, Dallas, TX); or β-actin (C4, Santa Cruz Technologies). ..

    Generated:

    Article Title: CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth
    Article Snippet: .. Expression of specific proteins was revealed by immunoblotting with antibodies directed against Dok-1, Dok-2, Shc, Csk, SHP-1, SHP-2, or SHIP-1 Ab, which were generated in the Veillette laboratory , ; Ras-GAP (B4F8; Santa Cruz Biotechnologies, Dallas, TX); or β-actin (C4, Santa Cruz Technologies). ..

    Article Title: CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth.
    Article Snippet: .. Expression of specific proteins was revealed by immunoblotting with antibodies directed against Dok-1, Dok-2, Shc, Csk, SHP-1, SHP-2, or SHIP-1 Ab, which were generated in the Veillette laboratory38,54; RasGAP (B4F8; Santa Cruz Biotechnologies, Dallas, TX); or β-actin (C4, Santa Cruz Technologies). ..

    Immunoprecipitation:

    Article Title: Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling
    Article Snippet: .. For immunoprecipitation, cell lysates were cleared and incubated with antibodies to mouse Dok-1 (A3) or Dok-2 (M20; Santa Cruz Biotechnology, Inc.) followed by incubation with protein G–Sepharose (Amersham Biosciences). ..



    Similar Products

    93
    Santa Cruz Biotechnology dok2 mouse monoclonal antibody
    Serum <t>anti-DOK2</t> antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.
    Dok2 Mouse Monoclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dok+2/Dok-2+Antibody/pmc12456515-154-5-11
    Average 93 stars, based on 1 article reviews
    dok2 mouse monoclonal antibody - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology mouse anti dok2 monoclonal antibody
    Serum <t>anti-DOK2</t> antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.
    Mouse Anti Dok2 Monoclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dok+2/Dok-2+Antibody/pmc12456515-139-8-15
    Average 93 stars, based on 1 article reviews
    mouse anti dok2 monoclonal antibody - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology anti dok2
    Serum <t>anti-DOK2</t> antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.
    Anti Dok2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dok+2/Dok-2+Antibody/us12351631-859-13-14
    Average 93 stars, based on 1 article reviews
    anti dok2 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology dok 2
    Serum <t>anti-DOK2</t> antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.
    Dok 2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dok+2/Dok-2+Antibody/pm40461553-481-13-30
    Average 93 stars, based on 1 article reviews
    dok 2 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc polyclonal antibodies against stat1, pstat1, dok-2, and pdok-2
    Serum <t>anti-DOK2</t> antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.
    Polyclonal Antibodies Against Stat1, Pstat1, Dok 2, And Pdok 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dok+2/anti+stat3/pmc08260471__res___129___280___s001-120-11-12
    Average 90 stars, based on 1 article reviews
    polyclonal antibodies against stat1, pstat1, dok-2, and pdok-2 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology antibodies recognizing arc
    Serum <t>anti-DOK2</t> antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.
    Antibodies Recognizing Arc, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dok+2/Dok-2+Antibody/pmc05698418-250-1-25
    Average 93 stars, based on 1 article reviews
    antibodies recognizing arc - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology primary mouse anti dok2
    Serum <t>anti-DOK2</t> antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.
    Primary Mouse Anti Dok2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dok+2/Dok-2+Antibody/pmc05652255-102-4-10
    Average 93 stars, based on 1 article reviews
    primary mouse anti dok2 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    Serum anti-DOK2 antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.

    Journal: Hepatology Communications

    Article Title: Identification of anti-DOK2 antibodies in patients with autoimmune hepatitis via a human protein microarray

    doi: 10.1097/HC9.0000000000000807

    Figure Lengend Snippet: Serum anti-DOK2 antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.

    Article Snippet: The following antibodies were used: DOK2 mouse monoclonal antibody (clone E-10; Santa Cruz Biotechnology, Inc.), CK7 mouse monoclonal antibody (clone OV-TL 12/30; Abcam, ab68459), HepPar-1 mouse monoclonal antibody (clone OCH1E5; Santa Cruz Biotechnology, Inc.).

    Techniques: Comparison

    Serum anti-DOK2 antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.

    Journal: Hepatology Communications

    Article Title: Identification of anti-DOK2 antibodies in patients with autoimmune hepatitis via a human protein microarray

    doi: 10.1097/HC9.0000000000000807

    Figure Lengend Snippet: Serum anti-DOK2 antibody levels in AIH patients following PSL treatment. (A) Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who achieved biochemical remission (left). Comparison of serum anti-DOK2 antibody levels at onset and posttreatment among AIH patients who did not achieve biochemical remission (right). p-v alues were calculated via the Wilcoxon matched-pairs signed-rank test; p <0.05 was considered significant. (B) Relationship between serum anti-DOK2 antibody and IgG levels posttreatment in patients with AIH. (C) Relationships between serum anti-DOK2 antibody levels and serum AST levels posttreatment in AIH patients. (D) Relationships between serum anti-DOK2 antibody levels and serum ALT levels posttreatment in AIH patients. p - v alues were calculated via the Wilcoxon matched-pairs signed-rank test. Abbreviations: AIH, autoimmune hepatitis; AU, arbitrary units; DOK, docking protein; PSL, prednisolone.

    Article Snippet: The tissue sections were incubated with a primary mouse anti-DOK2 monoclonal antibody (sc-17830; dilution 1:25; Santa Cruz Biotechnology Inc.) or a CD68 mouse monoclonal antibody (AT1379-1; Nichirei Bioscience Inc.) for 20 minutes at 25°C.

    Techniques: Comparison